FDA staff worries about risks of cancer, suicide in COPD drug Daxas

04/5/2010 | Reuters

FDA reviewers voiced concern about suicide and suicide attempts by clinical-trial patients who received Daxas, a drug for chronic obstructive pulmonary disease from Forest Laboratories and Nycomed. Forest said an analysis of the cases "does not suggest a causal relationship" with Daxas, which is also linked to a higher risk of cancer, according to FDA data.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR